FDA approves Fotivda for relapsed or refractory advanced renal cell carcinoma

Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump

Over the past three years, the American Cancer Society has recovered from the fundraising decline brought on by COVID-19 and has reversed the years-long fundraising slump in public support.

May 03, 2024

Vol.50 No.18

By Paul Goldberg

Health Equity White House

Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers

The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars.

May 03, 2024

Vol.50 No.18

By McKenzie Prillaman

Conversation with The Cancer Letter

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said in its final recommendation statement April 30.

May 03, 2024

Vol.50 No.18

By Matthew Bin Han Ong

Clinical Trials & Tribulations

Canine cancers as models: We have barely tapped the full potential of comparative oncology

In 2024, an estimated 6 million pet dogs will be diagnosed with cancer in the United States. As someone who has lost several family dogs to cancer, I know how heartbreaking this diagnosis will be for each of those dogs’ owners.

May 03, 2024

Vol.50 No.18

By Christina K. Lopes

In the Archives

Otis Brawley discusses health disparities, UChicago pioneering oncologists on the UChicago Cancer Luminaries Podcast

UChicago Medicine Comprehensive Cancer Center has launched the Cancer Luminaries podcast series to mark its 50th year as a National Cancer Institute-designated center.

May 03, 2024

Vol.50 No.18

In Brief

Cold Spring Harbor and Northwell extend collaboration with $150M commitment

Northwell Health President & CEO Michael Dowling and Bruce Stillman, President & CEO of Cold Spring Harbor Laboratory. Source: Northwell HealthThe Cold Spring Harbor Laboratory and Northwell Health have renewed their affiliation that was originally announced in 2015.

May 03, 2024

Vol.50 No.18

FDA approves Fotivda for relapsed or refractory advanced renal cell carcinoma

YOU MAY BE INTERESTED IN

Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump

Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

Canine cancers as models: We have barely tapped the full potential of comparative oncology

Otis Brawley discusses health disparities, UChicago pioneering oncologists on the UChicago Cancer Luminaries Podcast

Cold Spring Harbor and Northwell extend collaboration with $150M commitment

Renew today!

Subscriber content

Login